Who we are
Little Green Pharma is a privately-owned company based in Western Australia. In April 2017, the company was granted one of the few licenses in Australia by the Australian Government’s Federal Office of Drug Control to cultivate and produce Medical Cannabis for Australian patients from June 1st 2017.
We grow and produce premium medical grade cannabis in Australia for a global market. Bringing nature and science together, we bottle hope providing a safe, effective treatment choice for patients. Our unique manufacturing process is born from innovation, collaboration and a deep desire to help patients around the world.
How we are different?
Little Green Pharma has an advanced technology for producing Medical Cannabis for oral administration. The resulting preparations support very accurate dosing and achieve therapeutic effectiveness at significantly low cannabinoid doses.
What does this mean?
Our novel manufacturing technology ensures high bio-availability of the active cannabinoids, meaning that a therapeutic effect can be achieved with very low dosage rates combined with precise dosage control.
Where necessary, our manufacturing process can maintain the integrity of CBDA and THCA if required, avoiding the decarboxylation of important cannabinoids.
Our focus is on the manufacture of medicinal cannabis and related research in accordance with the requirements of the relevant Health and Regulatory Authorities within Australia.
Non-Executive Director and Chairman
Michael was appointed on 13 November 2018. His early Ernst & Young career was focused on auditing clients within the oil and gas sectors and added mining to his portfolio later. Michael also led Ernst & Young’s UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice. He has been involved advising companies on fundraising, re-organisations, transactions, corporate governance and IPOs. Michael is a former Chair of the Bureau and current member of UNECE’s Expert Group on Resource Classification and a non-executive director of Barloworld Limited, Senior Independent Director and Remuneration Committee Chair of Gem Diamonds Limited, Audit Committee Chair of Lenta Limited, and Deputy Chair and Nomination Committee Chair of Kaz Minerals plc.
Fleta was appointed on 29 May 2017 and has 17 years’ executive experience in corporate and consumer health markets. Over ten years, Fleta established, grew and sold one of Australia’s largest providers of workplace health services. She has since been involved in several start-ups including a water treatment technology business and a digital health engagement company based in Singapore. Fleta is a graduate of the Australian Institute of Company Directors (GAICD), holds a Bachelor of Science degree and an MBA from the University of Western Australia.
Angus was appointed on 19 February 2018 and is a Harvard Business School alumnus, a Chartered Accountant, a fellow of the Financial Services Institute of Australasia and is currently completing a Master of Science. He is the founder of a boutique venture capital firm, has been a director, CFO and company secretary of a number of ASX listed companies and was also the CFO of Erdenes Tavan Tolgoi, a company that owns the worlds largest coking coal deposit and was looking at a US$10b dual listing in London and Hong Kong. Prior to these appointments he was an Executive Director at EY in London and Australia specialising in initial public offerings of FTSE 100 and 250 companies.
Neale Fong was appointed on 13 November 2018 and is a registered medical practitioner with over 35 years in senior leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organisations.
He is currently Chair of the Western Australian Government Country Health Service Board, the Suicide Prevention Council, Professor of Healthcare Leadership at Curtin University, Executive Chairman of Bethesda Health Care, and a director on a number of health-related start up health companies. He is an experienced company director (ASX and private companies) and has been a Fellow of Australian Institute of Company Directors for 17 years.
He was formerly Director General of the Western Australian Department of Health and CEO of St John of God Hospital in Perth.
Neale was named a finalist in the 2010 WA Citizen of the Year Awards in the category of Community Service and awarded a Centenary Medal in 2011 for services to healthcare by the Australian Government.
Vanessa is Head of Practice at Avant Law in Melbourne. She has been practising in the areas of health law, risk management and compliance in the healthcare industry, insurance law and medical negligence for over 20 years. Vanessa has defended claims against doctors and hospitals, including catastrophic brain injury, and has represented doctors at numerous disciplinary hearings and coronial inquests. Vanessa has experience providing indemnity advice to insurers, advising on legislative changes and regularly presents to medical groups and doctors on medico legal issues.
Rohan Hardcastle spent the last ten years working as a barrister in Sydney across commercial and corporate disputes, disciplinary proceedings and public inquiries. He has a particular interest in regulatory work including: financial services, continuous disclosure, market manipulation and insider trading. He has acted for ASIC and defendants in these areas.
Rohan also has an interest in health law and genetics and is currently an ambassador for two not for profit groups in the healthcare space. He has published a book titled “Law and the Human Body: Property Rights, Ownership and Control” (Bloomsbury Publishing, Oxford, 2009).
Medical & Scientific Advisory Board
Clinical Professor Allan Kermode
Clinical Professor Allan Kermode is a Consultant Neurologist and Head of the Demyelinating Diseases Research at the Perron Institute, a Clinical Professor of Neurology at The University of Western Australia, and Head of the Department of Neurology and Clinical Neurophysiology at Sir Charles Gairdner Hospital. Recently, Professor Kermode was appointed Visiting Professor at Sun Yat-sen University in China’s Guangdong Province.
Professor Kermode sees patients with multiple sclerosis (MS), manages a research team investigating causes of MS, and is Professor of Immunology at the Institute for Immunology and Infectious Diseases (IIID). His broad training incorporates not only clinical neurology, clinical immunology, electrophysiology and neuroradiology, but also several years of virology, cellular immunology and molecular biology bench work.
Dr Paul Daeninck
Dr. Paul Daeninck is a medical oncologist and palliative medicine consultant with CancerCare Manitoba and the Winnipeg Regional Health Authority (WRHA) Palliative Care Program. He is the Chair of the Symptom Management and Palliative Care Disease Site at CancerCare Manitoba. He is an Assistant Professor and Leader for the Palliative Care Longitudinal Theme for Undergraduate Education at the College of Medicine, University of Manitoba.
Dr. Daeninck has served with several national organizations, including those of the Canadian Society of Palliative Care Physicians and Canadian Partnership Against Cancer. He sits on the Board of Directors of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), and is currently a co-chair of the Royal College Conjoint Advisory Committee on Palliative Medicine.
Facilitator | Electronics Engineer and Clinical Psychologist
Bill graduated in Electronics in 1961 and Clinical Psychology at UWA in 1989. In 2010 Bill undertook private research with Toronto University into the use of gold nano particles and RF excitation in tumour necrosis. This work resulted in Habi Pharma being awarded a patent associated with the process of preparing phytochemical materials for efficient nano sized delivery via a liposomal carrier. Bill continues to undertake voluntary work as a Clinical Psychologist at SCG Hospital and establishing Village Clean Water projects with Rotary Uganda.
Professor Bruce Sunderland
Emeritus Professor | Pharmacology
Bruce, an Emeritus Professor at the School of Pharmacy, Curtin University in Perth, WA specialises in drug delivery and drug stability research areas. Bruce has over 40 years’ experience as an academic pharmacist, teaching and researching in physical pharmacy, pharmaceutical technology and medicine formulation. He has published over 130 research publications in peer-reviewed journals.
Pharmaceutical Business Owner
Barry obtained his Chemistry degree from the Auckland University of Technology and has over 30 years of Pharmaceutical experience. He came to live in Perth in 1987 and started as an R&D Chemist at Delta West. Moved to the QC Department and after some years as Laboratory Supervisor, became the QC Manager. Delta West was purchased firstly by Pharmacia, Upjohn and finally Pfizer. He left employment with Pfizer and started at Princess Margaret Hospital, Pharmacy Department in the QC Manufacturing Department. Barry and his business partner started their current Pharmaceutical business in 1997 and have a Therapeutic Goods Administration Licence to produce scheduled pharmaceutical products. Obtained an ODC Licence and Permit to Manufacture Medical Cannabis finished products for LG Pharma in 2017.
Dr Chris Davis
Analyst | Physicist and Defence Analyst
Chris has a PhD in Physics from UWA. He did research at the universities of Florida and Sydney before joining the Department of Defence, where he was in charge of analysis of naval operations and technology. He led a branch of the Defence Science and Technology Group with staff in Sydney and Perth and was manager of the Group’s laboratory in Perth.
Fleta has 17 years’ executive experience in corporate and consumer health markets. Over ten years, Fleta established, grew and sold one of Australia’s largest providers of workplace health services. She has since been involved in several start-ups including a water treatment technology business and a digital health engagement company based in Singapore. Fleta is a graduate of the Australian Institute of Company Directors (GAICD), holds a Bachelor of Science degree and an MBA from the University of Western Australia.
Angus is a Harvard Business School alumnus, a Chartered Accountant, a fellow of the Financial Services Institute of Australasia and is currently completing a Master of Science. He is the founder of a boutique venture capital firm, has been a director, CFO and company secretary of a number of ASX listed companies and was also the CFO of Erdenes Tavan Tolgoi, a company that owns the worlds largest coking coal deposit and was looking at a US$10b dual listing in London and Hong Kong. Prior to these appointments he was an Executive Director at EY in London and Australia specialising in initial public offerings of FTSE 100 and 250 companies.
Chief Financial Officer & Company Secretary
Craig is a Fellow of the Institute of Chartered Accountants, a Fellow of the Governance Institute of Australia, a Graduate of the Australian Institute of Company Directors’ Course and holds a B.Com (Hons) degree in accounting and finance. He has over 20 years’ experience in auditing, accounting and financial management of resource, education, viticulture and other companies.
Dr Joe Kosterich
Medical Advisor (M.B.B.S.)
Dr Joe is a regular on TV and radio, writes for medical and mainstream publications, as well as maintaining a website and blog providing health information. Dr Joe held senior positions in the Australian Medical Association and sat on numerous industry and government boards. He has extensive corporate experience in the setting up and management of medical centres.
Head of Operations
Paul brings enterprise and clinic based wellness experience along with high-level strategic and technical management to the Little Green Pharma team. He has 15 years’ experience in the health industry having previously co-founded Australia’s largest provider of enterprise health services. In recent years, Paul has been involved in several successful start-up organisations within the Australian pharmacy and global health technology markets. In his role at Little Green Pharma Paul will take a hands-on role in the growth of the operational team and technology integration.
National Education Manager
Barb has over ten years’ experience in the pharmaceutical industry in both marketing and sales management roles with two global leaders and across a number of different disease states. She has spent the last three years widening her breadth of knowledge and experience working in technology start-ups. Barb has a Bachelor of Science degree and also has an MBA (Marketing Major) from Curtin Graduate School of Business.
Head of Pharmaceuticals
Damian is a registered pharmacist awarded MPharm(Hons), DipClinPharm with 20 years’ experience in hospital pharmacy and academia in the UK and Australia.
Damian has advanced skills in clinical pharmacy practice, clinical research, leadership, education and training. In recent years he has successfully led innovative medicines management systems redesign using project management and business improvement methodologies.
Head of Legal
Alistair has over 13 years’ experience as a legal advisor, primarily as in-house counsel with BHP in Singapore, Chile and Perth and as a solicitor with Freehills (now Herbert Smith Freehills). He has worked across various sectors, including energy & petroleum, international commodities trading, resource exploration and construction. He holds a Bachelor of Laws and Bachelor of Arts from the University of Western Australia and a Graduate Diploma in Applied Economics from Murdoch University.
Dr Leon Warne
Head of Research & Innovation
BSc(Biol), BBiomedSc(Hons1), BSc, BVMS, MVS, MANZCVS, Diplomate ACVAA, PhD
Leon is a researcher and academic with over 10 years’ experience in the field of pain medicine. He holds a Bachelor of Science in Biomedical Science, a Doctorate of Veterinary Medicine and a PhD in pain-management and assessment. Leon leads a translational researcher group investigating a novel genetic treatment for people suffering chronic neuropathic pain. His passion for research and development focused on providing integrative medical solutions to improve patient quality of life led Leon to his current role as Head of Research and Innovation at Little Green Pharma. His clinical research interests are assessment and management of pain in patients incapable of self-reporting; and utilisation of novel drug delivery technologies to optimise bioavailability and dosing efficacy of medicinal cannabis therapeutics.
Head of Marketing
Celia has over fifteen years’ experience in marketing management, two of these working in pharmaceutical, six in media and four years in primary healthcare. Before starting at Little Green Pharma she spent worked at Seven West Media focusing on digital marketing and holds a Bachelor of Commerce (Marketing).
Warren has a Diploma in Banking and Finance from Macquarie University in NSW, with a background in Finance, Banking and Office Management. He has held senior positions at both Management and Board level in the Health, Wellbeing and Aged Care over many years.